Pseudobulbar Affect (PBA) After Brain Injury

Pseudobulbar affect (PBA) is a neurological condition in which the brain loses control of emotional expression. The person experiences involuntary, sudden episodes of crying or laughing that do not match their actual emotional state or are out of proportion to what triggered them. It is not a mood disorder, and it is not a mental health condition. It is a disruption in the neural circuits that regulate how emotions are expressed outwardly.

For families and caregivers, PBA can be one of the most confusing and painful symptoms to witness. A person may burst out laughing at a funeral, cry uncontrollably over something small, or shift rapidly between both within minutes. Without a name for what is happening, families often interpret these episodes as manipulation, instability, or emotional regression. The behavior is none of those things. The brain is misfiring the signal between what the person feels internally and what comes out.

What causes pseudobulbar affect

PBA occurs when there is damage to the pathways connecting the cerebral cortex to the cerebellum and brainstem. These pathways are responsible for modulating emotional expression. When they are disrupted, the brain loses its ability to regulate how and when emotions are displayed. The result is involuntary emotional expression that operates independently of the person's actual mood.

Research published in Journal of Head Trauma Rehabilitation and reviewed by the National Institute of Neurological Disorders and Stroke identifies PBA as a distinct neurological syndrome separate from depression, bipolar disorder, and other mood conditions. The underlying cause is structural brain damage, not psychological instability.

PBA is associated with a wide range of neurological conditions including traumatic brain injury, chronic traumatic encephalopathy, amyotrophic lateral sclerosis, multiple sclerosis, stroke, Parkinson's disease, and dementia. It is considered significantly underdiagnosed. One study published in Advances in Therapy estimated that fewer than half of patients with PBA receive an appropriate diagnosis.

How PBA differs from depression and emotional lability

PBA is frequently mistaken for depression because both can involve crying. The distinction matters because the treatment approaches are completely different. Depression involves a persistent low mood, hopelessness, loss of interest, and a subjective experience of sadness or emptiness. A person with depression is usually sad when they cry.

A person with PBA may not feel sad at all. The crying episode can arise suddenly, last seconds to minutes, and stop just as abruptly. The person is often aware that their outward expression does not match what they actually feel, which can itself be distressing. Some people describe embarrassment, frustration, or exhaustion from episodes that happen in public or during routine interactions.

Emotional lability, which refers to mood instability and rapid emotional shifts, is also different from PBA. Lability involves actual changes in emotional state. PBA involves a disconnection between emotional state and emotional expression. A neurologist or neuropsychologist familiar with brain injury can usually differentiate between these presentations through clinical evaluation and history.

What PBA looks like in daily life

Episodes can be triggered by something minor, something unrelated to emotion entirely, or nothing obvious at all. A person might cry when answering a routine question, laugh when someone describes a painful situation, or cycle through both within a short conversation. The episodes are typically brief but can be intense and physically exhausting.

For the person experiencing PBA, the loss of control over emotional expression can be isolating. Social situations become unpredictable. They may withdraw from family gatherings, avoid phone calls, or stop participating in activities they previously enjoyed because they cannot predict when an episode will occur. This withdrawal is sometimes mistaken for apathy or loss of motivation, adding another layer of misinterpretation to an already complicated picture.

Caregivers and family members often report that PBA strains relationships significantly. A spouse may feel hurt when their partner laughs during a serious conversation. A child may feel confused or frightened by a parent's sudden crying. Without an explanation, these moments accumulate into a pattern that can look like indifference, instability, or intentional behavior.

PBA in the context of CTE, TBI, and FND

PBA appears across several of the conditions RNA covers in depth. In chronic traumatic encephalopathy, emotional dysregulation is one of the earliest and most documented features. The tau pathology that characterizes CTE affects the frontal and temporal regions heavily, disrupting the circuits involved in emotional regulation and expression. PBA in CTE can be mistaken for personality change, mood disorder, or behavioral problems for years before the underlying neurological picture becomes clearer.

In traumatic brain injury, PBA is associated with damage to white matter pathways that connect cortical and subcortical structures. The more diffuse the injury, the more likely these pathways are affected. Veterans with blast exposure and repeated concussive injury are at particular risk. PBA in this population is frequently misattributed to PTSD or depression, which can lead to treatment approaches that do not address the actual mechanism.

There is also meaningful overlap with functional neurological disorder, where involuntary and unpredictable neurological symptoms are a defining feature. A clinician experienced with both conditions can usually distinguish them, but families navigating either diagnosis benefit from understanding that involuntary symptom expression is a documented neurological reality, not performance or exaggeration.

How PBA is diagnosed

There is no single imaging test or biomarker that confirms PBA. Diagnosis is clinical, based on history, symptom pattern, and ruling out other conditions. The Center for Neurologic Study Lability Scale (CNS-LS) is a validated seven-item questionnaire used in clinical settings to screen for PBA. It asks about the frequency and nature of laughing and crying episodes relative to how the person actually feels.

Families play an important role in this process. Because the person with PBA may minimize or feel embarrassed by episodes, caregiver observations are often more complete than self-report. Documenting specific episodes, including what triggered them, how long they lasted, whether the person's mood matched the expression, and how frequently they occur, gives the treating clinician substantially more to work with than a general description of emotional changes.

If you are seeing these patterns in someone with a known brain injury diagnosis, bring them directly to a neurologist rather than a general practitioner. PBA is a neurologically specific condition and is most accurately evaluated by someone with that specialization.

Treatment options for PBA

The only medication currently approved by the U.S. Food and Drug Administration specifically for PBA is dextromethorphan hydrobromide and quinidine sulfate, sold under the brand name Nuedexta. It was approved in 2010 following clinical trials in patients with ALS and multiple sclerosis. The FDA prescribing information states explicitly that the mechanism by which dextromethorphan exerts therapeutic effects in PBA is not fully understood, though it is believed to involve modulation of sigma-1 receptors and NMDA receptors in the brain circuits responsible for emotional expression.

Clinical experience has extended Nuedexta use to patients with TBI, stroke, and dementia, though these uses are considered off-label. Some patients report meaningful reduction in episode frequency and intensity. Others see partial improvement. Response varies depending on the underlying condition, injury severity, and individual neurobiology.

Other medications sometimes used off-label for PBA include selective serotonin reuptake inhibitors and tricyclic antidepressants, though the evidence base for these is less robust than for Nuedexta. Medication decisions belong entirely to the prescribing clinician. RNA provides educational information about treatment options so families can have informed conversations with providers, not to guide individual medical decisions.

Beyond medication, behavioral strategies can help reduce the social and emotional impact of episodes. These include identifying and where possible avoiding known triggers, developing a brief explanatory script for social situations, and building awareness in close relationships so that episodes are understood rather than misinterpreted.

What caregivers should know

Living with someone who has PBA requires recalibrating how you read emotional expression. The outward display is not a reliable signal of internal state. Crying does not always mean distress. Laughing does not always mean the moment is not serious. The person's actual feelings may be entirely different from what their face and voice are communicating.

That recalibration is harder than it sounds. Human beings are wired to read facial expressions and respond to them. When the expression and the context do not match, the instinctive response is confusion, hurt, or frustration. Those reactions are understandable. They are also worth examining, because responding to the expression rather than the person can create distance that neither party intended.

Asking directly tends to work better than interpreting. A simple "how are you actually feeling right now" during or after an episode gives the person an opportunity to communicate what is real for them rather than what their face is showing. Over time, families often develop their own shorthand for navigating this. That kind of practical adaptation is exactly what RNA exists to support.

If you are managing a loved one's PBA alongside other neurological symptoms, caregiver burnout is a real and documented risk. The cognitive load of interpreting ambiguous emotional signals every day, on top of medication management, appointments, and daily care, accumulates. Recognizing that load and building in support is not optional. It is part of sustainable caregiving.

Further Reading

• CTE Early Warning Signs: What Families Should Know
• How to Support FND Episodes Calmly
• CTE Symptoms Explained: What Each One Means
• Caregiver Burnout Warning Signs
• Brain Injury 101: Start Here

Free Resource

RNA's free Caregiver Guide, Surviving and Thriving, was written specifically for families navigating brain injury, neurological decline, and the daily realities that come with it. It covers practical tools, communication strategies, and what to expect at each stage.

Download the Free Caregiver Guide

References

1. Work SS, et al. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Advances in Therapy. 2011.
2. Pioro EP. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs. 2011.
3. Brooks BR, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine. Neurology. 2004.
4. U.S. Food and Drug Administration. NUEDEXTA prescribing information. FDA.gov. 2010.
5. National Institute of Neurological Disorders and Stroke. Pseudobulbar affect information page. NINDS.
6. Garnock-Jones KP. Dextromethorphan/quinidine in pseudobulbar affect. CNS Drugs. 2011.